ממומן
FDA Scrutiny of AI Tools Parallels Ivermectin Policy Divide
As the healthcare industry evolves, federal oversight is increasingly challenged to keep pace with innovation. The FDA has begun reviewing AI mental health tools for safety and efficacy, marking a critical step in regulating emerging technology. At the same time, Ivermectin policies continue to provoke debate, highlighting longstanding tensions around medical oversight, public trust,...
0 תגובות 0 שיתופים 37 צפיות 0 ביקורות
ממומן
ממומן
ממומן